On December 17, 2021, BELLUS Health Inc. completed an agreement with a syndicate of underwriters comprising Jefferies, Evercore ISI and RBC Capital Markets as joint book-running managers, LifeSci Capital as lead manager, and H.C. Wainwright & Co. and Bloom Burton as co-managers relating to the public offering of 25,000,000 common shares valued at US$200 million.
The shares were sold at a public offering price of US$8.00 per common share. In addition, the Underwriters were granted a 30-day option to purchase up to an additional 3,750,000 common shares from BELLUS Health.
BELLUS Health intends to use the net proceeds of the offering primarily to fund research and development activities, general and administrative expenses, working capital needs and other general corporate purposes.
